# Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

> **NCT02949219** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 41 (actual)

## Conditions studied

- Metastatic Small Intestinal Adenocarcinoma
- Recurrent Small Intestinal Carcinoma
- Unresectable Small Intestinal Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02949219
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-24
- **Primary completion:** 2019-01-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02949219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02949219, "Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02949219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*